Clinical Trials

65 enrolled

Small Cell Lung Carcinoma

NCT04963088 2025-06-26

TALENT

Phase 1/2 Completed

65 enrolled

Stomach Neoplasms

NCT06573424 2025-05-01

Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC

124 enrolled

Colonic Neoplasms

NCT05021328 2025-02-07

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

Phase 1 Completed

13 enrolled

CNS

Brain Neoplasms

NCT04996758 2024-12-12

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

40 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT04691388 2024-12-05

A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor

29 enrolled

NSCLC

NCT04770688 2024-08-15

AUTOMAN

Phase 1/2 Completed

25 enrolled

Adenocarcinoma of Lung, Neoplasm Metastasis

NCT04860700 2024-06-12

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

27 enrolled

CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT05493995 2024-05-09

PAAG

66 enrolled

Pancreatic Neoplasms

NCT04271813 2024-04-23

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

30 enrolled

Colorectal Neoplasms

NCT04967079 2024-04-23

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Phase 1 Completed

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06367010 2024-04-16

Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients

8 enrolled

Head & Neck

Thyroid Neoplasms

NCT03906058 2023-10-25

Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

39 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04790409 2023-09-14

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

21 enrolled

Lung Neoplasms

NCT06015035 2023-08-29

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

17 enrolled

Esophageal Neoplasms

NCT03743129 2023-06-12

ALTER-L029

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05130515 2023-01-31

CC-ANNIE

6 enrolled

Gynecologic

Platinum-resistant Recurrent Clear Cell Ovarian Cancer

NCT05206656 2022-11-23

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

80 enrolled

Breast

Breast Neoplasms

NCT04507906 2022-06-28

Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC

Phase 1/2 Completed

21 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05303740 2022-03-31

Anlotinib Retrospective Study for Esophageal Cancer

300 enrolled

Esophageal Neoplasms

NCT04912128 2021-06-03

AnloSBRT

30 enrolled

Stereotactic Body Radiation Therapy

NCT03736837 2021-03-15

ALTER-L004

60 enrolled